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AbstrAct
Background: Sei-1 is an oncogene capable of inducing double minute chromosomes 
(DMs) formation. DMs are hallmarks of amplification and contribute to oncogenesis. 
However, the mechanism of Sei-1 inducing DMs formation remains unelucidated. 
Results: DMs formation significantly increased during serial passage in vivo 
and gradually decreased following culture in vitro. micro nuclei (MN) was found 
to be responsible for the reduction. Of the DMs-carrying genes, Met was found to 
be markedly amplified, overexpressed and highly correlated with DMs formation. 
Inhibition of Met signaling decreased the number of DMs and reduced the amplification 
of the DMs-carrying genes. We identified a 3.57Mb DMs representing the majority 
population, which consists of the 1.21 Mb AMP1 from locus 6qA2 and the 2.36 Mb 
AMP2 from locus 6qA2-3. 
Materials and Methods: We employed NIH-3T3 cell line with Sei-1 overexpression 
to monitor and characterize DMs in vivo and in vitro. Array comparative genome 
hybridization (aCGH) and fluorescence in situ hybridization (FISH) were performed to 
reveal amplification regions and DMs-carrying genes. Metaphase spread was prepared 
to count the DMs. Western blot and Met inhibition rescue experiments were performed 
to examine for involvement of altered Met signaling in Sei-1 induced DMs. Genomic 
walking and PCR were adopted to reveal DMs structure.
Conclusions: Met is an important promotor of DMs formation.
IntroductIon
Sei-1 is a cell cycle promotor and an identified 
oncogene [1] that is frequently amplified in different 
cancer types [1–4]. Sei-1 is capable of promoting 
tumorigenesis by enhancing cell proliferation and 
prohibiting cell apoptosis [5, 6]. The involvement of Sei-1 
in chromosome instability has also been reported [3, 7]. 
Recent findings primarily focused on Sei-1’s oncogenic 
ability and potential tumor promoting pathways. 
Mechanisms that involve chromosome alterations that are 
inflicted by Sei-1 were not fully elucidated.
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Double minute chromosomes (DMs) are round-circle, 
acentric double-strand extra-chromosome DNA that usually 
exist in pairs. The formation of DMs is usually regarded as an 
important sign of genome instability [8–11]. DMs are more 
likely to harbor amplified genes [12]. The overexpressions 
of amplified genes carried on DMs are usually detected in 
different tumor types [13]. Genes carried on DMs, such 
as MYC and DHFR [14–16], are commonly identified as 
tumor-promoting genes that facilitate cancer progress and 
chemotherapy resistance [17–20]. DMs were also reported 
to be associated with tumor malignancy and poor prognoses 
[21–24]. As the primary manifestation of gene amplification, 
DMs carry varieties of oncogenes that may become potential 
and effective targets for clinical treatment.
Although DMs may be naturally lost during cell 
growth [25, 26], DMs can be maintained if DMs carried 
genes endowed advantages toward the host cells under 
certain selective pressures [25]. It may explain why 
oncogenes are often enriched on DMs in cancer. Previous 
studies demonstrate that a low dose of hydroxyurea (HU) 
treatment can reduce the number of DMs in various 
human carcinoma cell lines in vitro and in vivo [27–30]
while ionizing radiation eliminates the amplified genes on 
DMs. Moreover, DMs could be captured inside MNs in 
tumor cells under HU and radiation treatment in numerous 
studies [31–33], and were exorcized from the cell with 
the MN capsules [22, 26]. Recent findings also revealed 
that the suppression of the DMs-carrying oncogenes can 
reduce the DMs population [34].
NIH-3T3 serves as a suitable model for the study 
of DMs in cancer biology. [35–38]. A previous study 
determined that Sei-1 overexpressing NIH-3T3 cells not 
only gain a growth advantage but also produce DMs in vivo 
[7]. This finding aroused interest regarding how DMs are 
generated and confer malignant phenotypes. To obtain a 
better understanding, we re-established an NIH-3T3 model 
with Sei-1 overexpression in vitro and in vivo. In this 
study, we innovatively investigated the mechanism of Sei-
1 inducing the formation of DMs in nude mouse. We found 
the number of DMs induced by Sei-1 was significantly 
increased during in vivo tissue passage but reduced during 
in vitro cell passage. Among the DMs-carrying genes, Met 
was the most prominently amplified and overexpressed. 
Met signaling pathway was shown to increase the Sei-1-
induced DMs population, which indicated a novel function 
of the well-known oncogene Met to induce the formation of 
DMs. Additionally, a 3.57 Mb DMs structure was identified 
to represent the majority population of DMs with two 
amplicon fragments that were jointed with blunt ends.
results
distinct evolution in dMs population between  
in vivo and in vitro
Sei-1 and null-vector-transfected NIH-3T3 cell clone 
Sei-1/NIH-3T3 and Vec (Figure 1A) were subcutaneously 
injected into nude mice. Consistent with previous result [7], 
Sei-1/NIH-3T3 successfully formed a xenografted tumor, 
whereas Vec failed. The original generation achieved from 
the primary culture of cell clone Sei-1/NIH-3T3 formed a 
xenograft that was named CPX1; the second generation 
was named CPX2, the third generation was named 
CPX3…CPX6 (Figure 1B). DMs were scarcely detected in 
CPX1 but distinctly grew in CPX3 and CPX6 (Figure 1C 
and 1D). A distinct situation was observed after in vitro 
maintenance of CPX6. The number of DMs substantially 
decreased after eight weeks; in 12 weeks, the number of 
DMs was significantly reduced compared with the primary 
cells (Figure 1E and 1F). The DOP-PCR products of the 
microdissected DMs were probed and applied to CPX6 
micronuclei spreads by FISH after different periods of 
in vitro maintenance. MNs that contain DMs signals 
were observed in these slides with the fluorescence signal 
substantially more condensed in MNs from early- to late-
maintained cells (Figure 1G). In addition, the percentage of 
high DMs-signal harboring MN also increased from early- 
to late-maintained cells (Figure 1H). These results showed 
opposite changes in the DMs population between in vivo 
passage and in vitro passage. The results also indicated that 
MNs were responsible for the expulsion of DMs during 
in vitro cell culture.
Genes carried on DMs were identified and 
overexpressed
To elucidate the characteristics of DMs, a mouse 
aCGH was applied to find origins of DMs amplification. 
A genome overview of the aCGH results showed two 
distinct amplicons in the neighborhood on chromosome 6 
(Supplementary Figure S1, Supplementary Table S1); no 
distinct amplified regions on other chromosomes were 
observed. A detailed aCGH probe-based graph revealed 
approximate sizes of the two amplicons, e.g., 1.21 Mb for 
AMP1 and 2.36 Mb for AMP2, with identical amplification 
levels (Figure 2A). The FISH analysis with randomly 
chosen BAC probes that match the amplified region 
confirmed that the amplicons locate on the DMs (Figure 2A 
and 2B; Supplementary Table S2). The amplified 
genes were identified and subsequently confirmed to 
settle on DMs by FISH (Supplementary Table S3), 
e.g., Met, Capza2, St7, Wnt2, Asz1, Ctfr, Cttnbp2 on 
AMP1 and Kcnd2, Tspan12, Ing3, Cped1, Wnt16, and 
Fam3c on AMP2. Quantitative real-time PCR confirmed 
that these genes were amplified on the DNA level and 
overexpressed in RNA (Figure 2C and 2D). Met was the 
most prominently overexpressed, which suggests that Met 
is the key activator of Sei-1-induced amplification. These 
results identified the exact genes carried on DMs; the 
majority of these genes were amplified and overexpressed, 
which indicates that these genes—especially Met—may 
actively enhance the tumorigenic and DMs-inducing 
potentials of Sei-1.
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Met signaling was activated as the dMs 
population increased
The previous results elucidated an increased 
expression pattern of genes carried on DMs. Met was 
predominantly increased. Met was a well-depicted 
oncogene that drove carcinogenesis in many tumor 
types. Thus, Met was probably the most important 
gene amplified by Sei-1. The members involved in Met 
signaling pathway were detected using the western blot; 
a progressive increase of Met, Gab-1, Pik3r1, Akt protein 
and phosphorylation levels from Sei-1/NIH-3T3, CPX3 
to CPX6 (Figure 3A and 3B) were discovered, which 
suggests that Met signaling pathway was activated during 
in vivo passage. Hepatocyte growth factor (Hgf) has 
been well elucidated to directly bind and motivate Met 
and its downward pathways. An alternative method of 
Met accumulation that causes self-phosphorylation and 
activation was also previously reported [39]. To determine 
what triggered Met signaling pathway, three activation 
sites of Met protein were tested using the western blot 
in Sei-1 overexpressing the Sei-1/NIH-3T3 clone and 
primary cell pool CPX3, CPX6 with and without mouse 
recombinant Hgf treatment (Figure 3C and 3D). The 
results showed that Met was found to be activated even 
without Hgf treatment; however, the activation levels were 
lower than those of the corresponding Hgf treated groups. 
Besides, Sei-1 expression was found to be significantly 
Figure 1: dMs population evolution in vivo and in vitro. (A) Western blot results show Sei-1 overexpression in NIH-3T3 cell 
clone Sei-1/NIH-3T3 compared with Vec. Upper, quantification of western blot results (n = 3), lower, representative western blot image. 
(b) Flow chart of in vivo and in vitro passage procedure. Three parallel procedures were employed, each mouse bore two tumor implants. 
(c) Metaphase spread images of primary cells CPX1, CPX3 and CPX6. Red arrows indicated the DMs. (e) Metaphase spread of CPX6 after 
four, eight, and 12 weeks of in vitro passage. (d) DMs count in CPX1, CPX3 and CPX6, for each group, n = 110 from three independent 
studies. (F) DMs number per karyotype in primary cells in four, eight, and 12 weeks of in vitro passage, n = 100 for each group. (G) FISH 
assays that show DMs signals in MNs after four, eight, and 12 weeks of in vitro passage. (H) The percentage of MNs with different staining 
states—“–”, no DMs signal, “+”, 0–50% DMs signal, and “++”–50% –100% DMs signals after four, eight, and 12 weeks of in vitro passage. 
Scale Bar, 10 μm. ***P < 0.001.
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higher in CPX6 compared to earlier generations of 
primary cells (Figure 3D and Supplementary Figure S2), 
suggesting that Sei-1 overexpression under in vivo 
condition remains consistent, although reasons for this 
elevated Sei-1 overexpression level was unclear. These 
findings suggested that the Met signaling pathway was 
activated as the number of DMs grew. It also suggested 
that Met primarily adopted self-activation manner during 
in vivo passage, although Hgf stimulation could still 
effectively activate Met.
Inhibition of Met signaling pathway reduced the 
dMs population.
Met signaling activation was closely correlated to 
an increased number of DMs. A previous study revealed 
a decrease in the expression level of the DMs-carrying 
genes can decrease the number of DMs in cancer cells 
[34]. A recent study showed that DMs can be discharged 
from cells through MNs by inhibition of ERK activity, 
which causes a decrease in the DMs population [40]. We 
employed a Met-specific inhibitor—C
21
H17Cl2FN2O2—
to separately block Met signaling in CPX3 and CPX6. 
The western blot verified the distinct inhibition of Met 
signaling in both CPX3 (Figure 4A and 4C) and CPX6 
(Figure 4B and 4D) for 24 and 48 hours of drug treatment. 
Metaphase spreads were prepared 0, 12, 24, and 36 hours 
after Met inhibition for these two cell pools. DMs 
count demonstrated a significant reduction in the DMs 
population in both CPX3 and CPX6 cells at 24 hours and 
especially at 36 hours for inhibitor treatment (Figure 4E 
and 4F). Quantitative real-time PCR results revealed that 
the DMs-carrying genes (Met, Tspan12, Fam3c, and Ing3) 
were distinctly decreased 24 hours after Met inhibition as 
Figure 2: Identification of amplicons and amplified genes on DMs. (A) Schematic of aCGH (Sei-1/NIH-3T3 vs CPX6) shows 
amplicons on chr6qA2-3; amplified BAC probes were represented as red dots, deleted probes were represented as green dots, and the 
normal probes as black dots. The BAC clones that were employed to validate the amplicons were labeled in corresponding positions of 
chromosomes. (b) Representative FISH images using the BAC clones that are shown in red; scale bar, 10 μm, quantitative real-time PCR 
results of DNA amplification level (c) and mRNA expression level (d) show amplification and overexpression of genes carried on DMs. 
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a result of the loss of DMs (Figure 4G and 4H). These 
findings conclusively showed that Met signaling inhibition 
reduces the DMs population and proved that Met signaling 
was responsible for the Sei-1-induced formation of DMs. 
AMP1 and AMP2 were directly jointed by blunt 
ends 
Well-delineated DMs structures may explain 
their evolutionary traces. Two juxtaposing amplicons 
(AMP1 and AMP2) with nearly identical copy changes 
were identified in this study: four breakpoints, namely, 
BP1, BP2 on the edge of AMP1, and BP3, BP4 on the 
edge of AMP2, which suggests a relatively simple DMs 
structure. Based on the aCGH results, a set of primers 
(Supplementary Table S4) were designed to narrow the 
gaps among amplicons (Figure 5A). Genomic walking 
technology was subsequently adopted to amplify the 
flanking fragments of BP1 and BP2, whose sequence 
information was subsequently achieved by Sanger 
sequencing. The sequencing results presented classic 
blunt-end junctions of both BP4-BP1 and BP2-BP3 
(Figure 5B). Therefore, a diagram of a DMs structure with 
these two amplicons directly connected was constructed 
(Figure 5C). Dual-color FISH was conducted to confirm 
this structure with probes from two amplicons. We 
discovered that the majority of signals were perfectly 
merged; however, we did observe some cross-merged 
signals (Supplementary Figure S3), which suggests the 
minor existence of more complex structures that need to 
be studied and identified in a further study. In our model, 
we provide a relatively simple DMs structure induced 
by Sei-1 that perfectly matches the aCGH results, which 
probably represents the majority population of DMs; 
however, other subtypes of DMs still existed due to 
heterogeneity of DMs. 
Figure 3: Met signaling was activated during in vivo passage. (A) Western blot results show increases of Met/PI3K/Akt pathway 
from Sei-1/NIH-3T3, CPX3 to CPX6 during in vivo passage. (b) Quantification of protein level in A, n = 3. (c) Met phosphorylation was 
increased in the presence (“+”) of Hgf treatment from Sei-1/NIH-3T3, CPX3 to CPX6, at a dosage of 20 ng/ml, and absence (“–“) of Hgf 
treatment from Sei-1/NIH-3T3, CPX3 to CPX6 by in vivo passage. (d) Quantification of protein level in C with (+) or without (–) Hgf 
treatment, n = 3. *P < 0.05; **P < 0.01; ***P < 0.001.
Oncotarget56669www.impactjournals.com/oncotarget
dIscussIon
Sei-1 is a newly discovered oncogene that is 
particularly found to be able to induce the formation of 
DMs. The biological connection between its oncogenic and 
DMs inducing abilities was barely explored. In this study, 
we innovatively observed the gain/loss of Sei-1-induced 
DMs to investigate oncogenic mechanism of Sei-1. 
Our study discovered Met as a dynamic responder to 
enhanced Sei-1 oncogenic function. We uniquely found 
that Met was not only amplified in the form of DMs 
and overexpressed but also significantly involved in the 
formation of DMs itself, suggesting a novel function of 
Met to generate the DMs.
Clinical research reported DMs to worsen the 
cancer prognosis. [23, 24]. Evidence also proved tumor 
malignancy could be alleviated by eliminating DMs 
in ovarian cancer [34], nominating DMs elimination 
as promising strategy for therapy. Distinct evolution 
of DMs populations under different circumstances 
has been previously reported [41]. We observed vast 
increase of DMs in vivo, but progressively DMs lost 
during in vitro culture. A Darwinian selection pattern 
was previously implied to explain the increased 
number of DMs that harbor MYCN in neuroblastoma 
cells [42]. Recent report found the amplification-linked 
extrachromosomal mutations (ALEMs) that occurred 
on DMs were significantly lost after in vitro passages. 
They hypothesized that the number of DMs could change 
dynamically as a response to significant environmental 
changes [43]. Sei-1-induced DMs probably facilitate 
the survival of cells under in vivo pressure. In vitro, 
endogenous microenvironment pressure was retreated, and 
previous growth advantage conferred by DMs was lost. 
Therefore, DMs production was restricted, which caused a 
reduction in DMs populations. Interestingly, we observed 
the Sei- 1 overexpression level significantly higher in 
CPX6 compared to Sei-1/NIH-3T3, CPX1, CPX3 both 
in cells and tumor tissues (Figure 3D, Supplementary 
Figure  S2), for which the reasons were unclear. We 
suspected that under in vivo condition Sei-1 expression 
level could somehow be enhanced to further increase the 
number of DMs.
DMs-carrying oncogenes were responsible for the 
malignant phenotype in cancer cells with DMs. These 
genes were most likely overexpressed but not always [44]. 
In this study, multiple oncogenes carried on DMs were 
both amplified and overexpressed, such as Met, Wnt2, 
Tspan12, Wnt16 and Fam3c. Met can enhance various 
cancer malignancies [45–48] and concur poor diagnosis 
Figure 4: Met inhibition caused a loss in dMs. Western blot results show effective inhibition in CPX3 (A) and CPX6 (b) for 24 
and 48 hours with 4 × 10–4 μg/ml Met inhibitor treatment. Quantification data are shown in (c) (CPX3) and (d) (CPX6), n = 3. Scatter plot 
show a significant decrease in the DMs population 12, 24, and 36 hours with Met inhibition in (e) CPX3 and (F) CPX6, for each group, 
n = 100 from three independent studies. Quantitative real-time PCR results show decreased expression levels of DMs-carrying genes with 
Met inhibition in (G) CPX3 and (H) CPX6. A two-tailed student’s t-test was employed as statistics; *P < 0.05, **P < 0.01, ***P < 0.001.
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of cancer [49]. Here, we found Met overexpression to be 
the most prominent among all amplified genes, verifying 
Met to be a key activator involved in Sei-1’s function 
in tumorigenesis and DMs induction. It’s not hard to 
contemplate that Sei-1 overexpression dynamically 
enhanced Met signaling pathway that could further obliged 
in a more aggressive tumor progress. Met has been found 
amplified on DMs in some tumors [15, 50] and cancer 
mouse models [51], which implies that Met is a hotspot of 
gene amplification and may participate in DMs formation. 
Nevertheless, participation of Met signaling pathway in 
accelerating DMs population was seldom reported before. 
Our results showed a positive correlation between self-
activated Met signaling pathway and DMs formation. The 
inhibition of Met signaling pathway produced a significant 
loss of DMs, which proved that this pathway robustly 
promoted the formation of DMs. Therefore, Met signaling 
pathway may be a promising therapeutic target in treating 
tumors that contain DMs.
Episome excision model [52] and bridge-fusion-
breakage (BFB) model [53] were two classical theories 
to explain DMs formation, though detailed mechanisms 
remain elusive. In this study, we located the boundaries of 
two amplicons which were jointed in blunt ends. Blunt-
end joint suggested the involvement of a non-homology 
end junction (NHEJ) during the connection of the two 
amplicons. NHEJ was also responsible for other structure 
types, such as micro-homologies, anonymous insertions 
and palindrome sequences [54]. None of these structures 
was identified in this study. 
Clinical samples were always found to bear 
compound genomic lesions. Complex genomic alteration 
could result from long-term accumulation as response 
to a series of selective pressure in vivo [44]. DMs may 
Figure 5: DMs structures consist of two individual amplicons. (A) The boundaries of AMP1 and AMP2 were defined 
by quantitative real-time PCR for BP1, 2 and 4, and semi-quantitative PCR for BP3. (b) Blunt-end joints were identified via Sanger 
sequencing. AMP1 is shown in red and AMP2 is shown in green. (c) A schematic of DMs structures with DMs-carrying genes marked in 
the corresponding positions; the arrows indicate the transcription direction of each gene.
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experience multiple structural alterations from the original 
structure to more complex structures [44]. The two 
identically amplified amplicons comprising the DMs highly 
matches the aCGH result. Dual-color FISH indicated that 
this simple structure of DMs was the most prevalent. The 
minority cross-unmerged signals indicated the existence 
of distinguished DMs structures, although these DMs all 
came from the two amplicons on chromosome 6, which 
suggests that the simple structure represents the primitive 
and ancestry DMs induced by Sei-1 while the otherwise 
structured DMs probably derive from the simple-structured 
DMs. The simple-structured DMs probably provide the 
universal template for subsequent DMs evolution. Due 
to the complexity of environment pressure and medical 
intervention experienced by the tumor cells clinically, 
direct investigation of DMs structures in clinical samples 
may be profoundly challenging. DMs originally induced 
by Sei-1 was quite briefly structured, which suggested the 
Sei-1 overexpression model could be adopted as promising 
material for studying the initial event during the formation 
of DMs. 
MAterIAls And MetHods
Ethic statement
Animal experiments in this manuscript have been 
conducted in accordance with the ethical standards and 
according to the Declaration of Helsinki and has been 
approved by the Ethnic Committee of Harbin Medical 
University (Approval identifier: HMUIRB20160009).
cell line and transfection
NIH-3T3, a mouse embryo originated fibroblastic 
cell line [55], was purchased from American Type Culture 
Collection (ATCC, Manassas, VA). The cell line was 
further authenticated through STR test by Microread 
(Beijing, China) and cultured with Dulbecco’s modified 
Eagle’s medium (DMEM; GIBCO, Carlsbad, CA) with 
10% fetal bovine serum (PAA Laboratories GmbH, 
Pasching, Austria) in 37 °C incubator (Thermo Fisher, 
Waltham, MA) supplied with 5% CO2. Primary cell 
culture and cell passage was conducted using standard 
procedure. Sei-1 CDS were cloned into pcDNA3.1(+) 
plasmid (Invitrogen, Auckland, New Zealand) and 
transfected into cells with Lipofectamine 2000 
(Invitrogen).
Animal experiment
Five-week-old Balb/c female nude mice were 
obtained from SLAC laboratory (Shanghai, China) and 
maintained within individual ventilated cages in SPF-
degree conditions. The s.c. xenograft was conducted 
as previous [7], with each mouse bearing two points of 
cell injection (one for Vec and one for Sei-1/NIH-3T3). 
Three Sei-1/NIH-3T3 tumors formed. Three mice were 
used each time of tissue transplant as independent studies, 
each mouse bearing two identical implantations of Sei-1/
NIH-3T3 tumor. When tumor size reached 2cm x 2cm, 
partial tumors from three mice were transplanted in three 
other mice separately while the rest from each mouse 
were primarily cultured to obtain cells for independent 
experiments. In tissue transplant, solid tumors were 
instantly separated after sacrifice and cut into ~1 mm³ 
dices. Five tumor dices were subcutaneously engrafted 
into another mouse.
Metaphase spread preparation
Colcemid (Sigma-Aldrich, St. Louis, MO) 
was added to the medium of fast growing cells for 2 
hours, which were trypsinized, washed with PBS, and 
subsequently centrifuged. Suspend pellets in pre-warmed 
0.075 M KCl and incubate in 37 °C water bath for 
exact 14 min. Fixate the cells by fresh fixative solution 
(mixture of 3 methanol: 1 acetic acid) three times. Drop 
the cell suspension on a clean slide. The slides were dyed 
with Giemsa and photographed using Olympus BX41 
microscope (Melville, NY, USA) equipped with JVC TK-
C75U color video camera (JVC, Japan). 
Micronuclei spread preparation
A micronuclei spread was prepared without 
colcemid treatment. The protocol, including Giemsa dying 
and image capturing, was identical to metaphase spread.
Fluorescence in situ hybridization (FIsH)
BAC clones purchased from the BACPAC 
Resources Center (Children’s Hospital Oakland, Oakland, 
CA) were labeled with fluorescence dUTPs and hybridized 
to metaphase/micronuclei spread as described [56]. The 
slides were counterstained with DAPI (Millipore, Billerica, 
MA) and observed and photographed using Leica DM-
RXA2 fluorescence microscope (Wetzlar, Germany). 
High-resolution photos were captured and analyzed using 
the MetaMorph Imaging System (Universal Imaging 
Corporation, West Chester, PA).
Mouse genome aCGH
Genomic DNA samples were extracted from fresh 
xenograft tissue with the DNeasy Blood & Tissue Kit 
(Qiagen, Valencia, CA). Sample quality was guaranteed by 
Nanodrop (Thermo Fisher, Waltham, MA). The samples 
were properly predisposed and applied to a SurePrint G3 
Mouse CGH Microarray (Agilent technologies, Santa 
Clara, CA). The procedures were conducted by Shanghai 
Biotechnology Co., Ltd. (Shanghai, China).
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DMs micro-dissection and degenerate 
oligonucleotide primed-polymerase chain 
reaction (DOP-PCR) 
The DMs were micro-dissected from NIH-3T3 
metaphase karyotype that were prepared as previously 
described [56]. The samples were administered with 
Topoisomerase I (Promega Corp., Madison, WI) and 
amplified using Sequenase version 2.0 DNA polymerase 
(United States Biochemical Corporation, Cleveland, 
OH) and a commonly adopted degenerate primer 
(5′-CCGACTCGAGNNNNNNATGTGG-3′). 
Semi-quantitative PCR and real-time 
quantitative PCR 
Genomic DNA and RNA samples were extracted 
by QIAamp® DNA Mini and Blood Mini Kit (Qiagen) 
and Trizol (Roche, Alameda, CA). cDNA samples were 
obtained using Transcriptor First Strand cDNA Synthesis 
Kit (Roche). For quantitative real-time PCR, the samples 
were tested using the LightCycler® 480 instrument (Roche) 
and corresponding SYBR Green I master (Roche). Semi-
quantitative PCR was performed as described [57].
Genome walking
The Universal Genomic Walker Kit (Clontech 
Laboratories., Mountain View, CA) was employed 
according to the manufacture instructions. The PCR 
products were sequenced and aligned with the mouse 
genome using the BLAT tool online from UCSC. The 
gene-specific primers (GSP) for BP1 were GSP1, 
5′-TTGGTATTTATTCACGACTTTGATAC-3′, GSP2, 
5′-GTCATGTACTCTGTTAAGACTGCTTT-3′. The GSP 
primers for BP2 were GSP1, 5′-AACAGATGAA 
AAAAAGTTGAGAGGCT-3′, GSP2, 5′- AACAGATGA 
AAAAAAGTTGAGAGGCT-3′
Western blot
Cells were lysed by RIPA buffer and sonication, and 
centrifuged at 12000 g 4°C for 30 minutes. Supernatant 
protein was separated by SDS-polyacrylamide gel, and 
transferred to PVDF membrane, which was scanned by 
Odyssey Imaging System (Li-COR, Lincoln, NE) after 
incubation of corresponding antibodies. Image J Software 
was used for quantification.
Antibodies and reagents
Antibodies against Gab1—phospho-Gab1, Met—
Phospho-Met, pan-AKT—Phospho-Akt, PI3K, and 
Phospho-PI3K were purchased from Cell Signaling 
(Danvers, MA). Antibodies against Hgf were purchased 
from Thermo Fisher (Waltham, MA). Anti-mouse and 
anti-rabbit antibodies were obtained from Rockland 
Immunochemicals (Gilbertsville, PA, USA). Mouse 
recombinant Hgf and c-Met Kinase Inhibitor III were 
purchased from Millipore (Billerica, MA). 
statistical analysis
Data of the DMs counts and Western blot coming 
evenly from three parallel studies were presented as the 
mean ± S.D. All experiments were independently repeated 
three times. Two-tailed Student’s t-test as well as one-way 
ANOVA with SNK test were employed as the statistics.
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